

1. Record Nr.	UNINA9910878983003321
Autore	Gemma Akihiko
Titolo	Analysis File of Drug-Induced Lung Injury : Expert Opinion for Analysis of Big Data // by Akihiko Gemma
Pubbl/distr/stampa	Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024
ISBN	9789819734467 9789819734450
Edizione	[1st ed. 2024.]
Descrizione fisica	1 online resource (122 pages)
Disciplina	616.2
Soggetti	Respiratory organs - Diseases Medical genetics Diseases - Causes and theories of causation Oncology Pharmacology Genetics - Research Pneumology Clinical Genetics Pathogenesis Genetics Research Malalties de l'aparell respiratori Farmacologia Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib,

alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).

---

## Sommario/riassunto

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.

---